A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Identifieur interne : 001C03 ( PubMed/Checkpoint ); précédent : 001C02; suivant : 001C04A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.
Auteurs : Kia Schulze [Allemagne] ; Caroline Staib ; Hermann M. Sch Tzl ; Thomas Ebensen ; Volker Erfle ; Carlos A. GuzmanSource :
- Vaccine [ 0264-410X ] ; 2008.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques, Administration par voie nasale, Animaux, Anticorps antiviraux (immunologie), Immunité cellulaire, Immunoglobuline A (immunologie), Injections musculaires, Lipopeptides (immunologie), Protéines nucléocapside (immunologie), Rappel de vaccin (), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Virus de la vaccine (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Vaccins antiviraux.
- immunologie : Anticorps antiviraux, Immunoglobuline A, Lipopeptides, Protéines nucléocapside, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus de la vaccine, Virus du SRAS.
- Adjuvants immunologiques, Administration par voie nasale, Animaux, Immunité cellulaire, Injections musculaires, Rappel de vaccin, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Adjuvants, Immunologic, Administration, Intranasal, Animals, Antibodies, Viral (immunology), Immunity, Cellular, Immunization, Secondary (methods), Immunoglobulin A (immunology), Injections, Intramuscular, Lipopeptides (immunology), Mice, Mice, Inbred BALB C, Nucleocapsid Proteins (immunology), SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Vaccinia virus (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , immunology : Antibodies, Viral, Immunoglobulin A, Lipopeptides, Nucleocapsid Proteins, Viral Vaccines.
- chemical : Adjuvants, Immunologic.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, Vaccinia virus.
- methods : Immunization, Secondary.
- prevention & control : Severe Acute Respiratory Syndrome.
- Administration, Intranasal, Animals, Immunity, Cellular, Injections, Intramuscular, Mice, Mice, Inbred BALB C.
Abstract
Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.
DOI: 10.1016/j.vaccine.2008.09.006
PubMed: 18805454
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:18805454Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.</title>
<author><name sortKey="Schulze, Kia" sort="Schulze, Kia" uniqKey="Schulze K" first="Kia" last="Schulze">Kia Schulze</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig</wicri:regionArea>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>D-38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
</author>
<author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M" last="Sch Tzl">Hermann M. Sch Tzl</name>
</author>
<author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
</author>
<author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
</author>
<author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzman">Carlos A. Guzman</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18805454</idno>
<idno type="pmid">18805454</idno>
<idno type="doi">10.1016/j.vaccine.2008.09.006</idno>
<idno type="wicri:Area/PubMed/Corpus">001A64</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A64</idno>
<idno type="wicri:Area/PubMed/Curation">001A64</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A64</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001C03</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C03</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.</title>
<author><name sortKey="Schulze, Kia" sort="Schulze, Kia" uniqKey="Schulze K" first="Kia" last="Schulze">Kia Schulze</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig</wicri:regionArea>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>38124 Braunschweig</wicri:noRegion>
<wicri:noRegion>D-38124 Braunschweig</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
</author>
<author><name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M" last="Sch Tzl">Hermann M. Sch Tzl</name>
</author>
<author><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
</author>
<author><name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
</author>
<author><name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzman">Carlos A. Guzman</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Administration, Intranasal</term>
<term>Animals</term>
<term>Antibodies, Viral (immunology)</term>
<term>Immunity, Cellular</term>
<term>Immunization, Secondary (methods)</term>
<term>Immunoglobulin A (immunology)</term>
<term>Injections, Intramuscular</term>
<term>Lipopeptides (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Nucleocapsid Proteins (immunology)</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Vaccinia virus (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Immunité cellulaire</term>
<term>Immunoglobuline A (immunologie)</term>
<term>Injections musculaires</term>
<term>Lipopeptides (immunologie)</term>
<term>Protéines nucléocapside (immunologie)</term>
<term>Rappel de vaccin ()</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Virus de la vaccine (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin A</term>
<term>Lipopeptides</term>
<term>Nucleocapsid Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunoglobuline A</term>
<term>Lipopeptides</term>
<term>Protéines nucléocapside</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins antiviraux</term>
<term>Virus de la vaccine</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>Vaccinia virus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term>
<term>Animals</term>
<term>Immunity, Cellular</term>
<term>Injections, Intramuscular</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Administration par voie nasale</term>
<term>Animaux</term>
<term>Immunité cellulaire</term>
<term>Injections musculaires</term>
<term>Rappel de vaccin</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18805454</PMID>
<DateCompleted><Year>2009</Year>
<Month>04</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0264-410X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>26</Volume>
<Issue>51</Issue>
<PubDate><Year>2008</Year>
<Month>Dec</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>6678-84</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2008.09.006</ELocationID>
<Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a serious infectious disease caused by the SARS coronavirus. We assessed the potential of prime-boost vaccination protocols based on the nucleocapsid (NC) protein co-administered with a derivative of the mucosal adjuvant MALP-2 or expressed by modified Vaccinia virus Ankara (MVA-NC) to stimulate humoral and cellular immune responses at systemic and mucosal levels. The obtained results demonstrated that strong immune responses can be elicited both at systemic and mucosal levels following a heterologous prime-boost vaccination protocol consisting in priming with NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schulze</LastName>
<ForeName>Kia</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Inhoffenstrasse 7, D-38124 Braunschweig, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Staib</LastName>
<ForeName>Caroline</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schätzl</LastName>
<ForeName>Hermann M</ForeName>
<Initials>HM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ebensen</LastName>
<ForeName>Thomas</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y"><LastName>Erfle</LastName>
<ForeName>Volker</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y"><LastName>Guzman</LastName>
<ForeName>Carlos A</ForeName>
<Initials>CA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055666">Lipopeptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>DZX5IUA94D</RegistryNumber>
<NameOfSubstance UI="C106335">macrophage stimulatory lipopeptide 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055666" MajorTopicYN="N">Lipopeptides</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014616" MajorTopicYN="N">Vaccinia virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year>
<Month>02</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>08</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>09</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>4</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>9</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18805454</ArticleId>
<ArticleId IdType="pii">S0264-410X(08)01215-2</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2008.09.006</ArticleId>
<ArticleId IdType="pmc">PMC7115531</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>BMJ. 2003 Apr 19;326(7394):850-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12702616</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 2003 Jun 20;300(5627):1961-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12766206</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2003 Aug;77(15):8394-407</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12857909</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Zhonghua Nei Ke Za Zhi. 2003 Sep;42(9):643-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14514395</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2269-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15755609</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Lett. 2004 Apr 15;92(3):237-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2007 Dec;81(24):13365-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17913799</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15096611</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2003 Feb;84(Pt 2):361-368</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12560568</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Respirology. 2003 Nov;8 Suppl:S9-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15018127</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2007 Jul 5;363(2):288-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17331558</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JAMA. 2003 Jun 4;289(21):2801-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12734147</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Med. 2006 Feb;3(2):e27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16379499</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Agent Cancer. 2007 Jul 10;2:14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17623060</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2006 Aug 28;24(35-36):6088-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16828529</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Avian Pathol. 2003 Dec;32(6):567-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14676007</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cancer Res. 2003 Nov 15;63(22):7942-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14633725</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Mar;79(5):2678-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15708987</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Exp Med Biol. 1995;380:221-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8830483</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Lett. 2004 Sep;95(2):139-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15388253</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2005 Jan;86(Pt 1):211-215</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15604448</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Immunol. 2002 Oct;32(10):2857-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12355438</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virology. 2005 Jan 5;331(1):128-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15582659</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2004 Apr 22;350(17):1731-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15102999</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chin Med J (Engl). 2003 Sep;116(9):1283-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14527349</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2007 Sep 1;179(5):2797-807</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17709493</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Immunol. 1998 Mar;28(3):1069-77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9541603</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Mol Biol. 2008 Feb 8;376(1):23-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18155731</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Respirology. 2003 Nov;8 Suppl:S20-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15018129</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Nov;78(22):12672-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15507655</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2005 Mar 18;23(17-18):2273-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15755610</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1997 Oct;71(10):7889-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9311878</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>JAMA. 2003 Jul 16;290(3):374-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12865379</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2006 Mar;87(Pt 3):641-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16476986</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 1993 Oct;74 ( Pt 10):2061-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8409930</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(8):3930-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15047809</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Appl Microbiol Biotechnol. 2005 Aug;68(2):220-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15660214</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Methods Mol Med. 2003;87:51-68</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12958449</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2006 Mar 15;24(12):2049-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16406225</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Pneumologie. 2007 Oct;61(10):663-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17763311</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Dec 10;325(2):445-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15530413</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
</list>
<tree><noCountry><name sortKey="Ebensen, Thomas" sort="Ebensen, Thomas" uniqKey="Ebensen T" first="Thomas" last="Ebensen">Thomas Ebensen</name>
<name sortKey="Erfle, Volker" sort="Erfle, Volker" uniqKey="Erfle V" first="Volker" last="Erfle">Volker Erfle</name>
<name sortKey="Guzman, Carlos A" sort="Guzman, Carlos A" uniqKey="Guzman C" first="Carlos A" last="Guzman">Carlos A. Guzman</name>
<name sortKey="Sch Tzl, Hermann M" sort="Sch Tzl, Hermann M" uniqKey="Sch Tzl H" first="Hermann M" last="Sch Tzl">Hermann M. Sch Tzl</name>
<name sortKey="Staib, Caroline" sort="Staib, Caroline" uniqKey="Staib C" first="Caroline" last="Staib">Caroline Staib</name>
</noCountry>
<country name="Allemagne"><noRegion><name sortKey="Schulze, Kia" sort="Schulze, Kia" uniqKey="Schulze K" first="Kia" last="Schulze">Kia Schulze</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001C03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:18805454 |texte= A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:18805454" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |